Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Mylan NV    MYL   NL0011031208

MYLAN NV

(MYL)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/14/2019 08/15/2019 08/16/2019 08/19/2019 08/20/2019 Date
18.04(c) 17.61(c) 18.53(c) 19.19(c) 19.48 Last
10 822 662 6 476 573 5 974 239 5 654 953 2 075 716 Volume
-8.52% -2.38% +5.22% +3.56% +1.51% Change
More quotes
Financials (USD)
Sales 2019 11 640 M
EBIT 2019 3 222 M
Net income 2019 514 M
Debt 2019 11 715 M
Yield 2019 -
Sales 2020 11 967 M
EBIT 2020 3 297 M
Net income 2020 937 M
Debt 2020 11 954 M
Yield 2020 -
P/E ratio 2019 14,9x
P/E ratio 2020 9,92x
EV / Sales2019 1,86x
EV / Sales2020 1,83x
Capitalization 9 900 M
More Financials
Company
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North... 
Sector
Pharmaceuticals
Calendar
11/11Earnings Release
More about the company
Surperformance© ratings of Mylan NV
Trading Rating : Investor Rating :
More Ratings
Latest news on MYLAN NV
08/19Health Care Higher as Pharma Fears Fade -- Health Care Roundup
DJ
08/16A SUMMER WELL SPENT : Mylan's 2019 North America Interns
PU
08/15MYLAN : “Sky's the Limit” When Encouraging Students to Embrace STEM
PU
08/13MYLAN : Behind a Shared Mission for Access, Mylan Sponsors Free Dental Clinic
PU
08/12No-deal Brexit could deepen Europe's shortage of medicines - experts
RE
08/02Tax Cuts Help Keep U.S. Companies Home -- WSJ
DJ
08/01Inversion Reversions Arrive as Companies Get Smaller Tax Edge From Foreign Ad..
DJ
07/30Tech pulls Wall Street lower on Trump trade warning
RE
07/30Health Care Down as Pfizer Weakness Offsets Merck Strength -- Health Care Rou..
DJ
07/30Pfizer Down Nearly 6%, on Track for Largest Percent Decrease in Over a Decade..
DJ
More news
Analyst Recommendations on MYLAN NV
More recommendations
Sector news : Pharmaceuticals - NEC
05:49aElanco to buy Bayer's animal health unit for $7.6 billion
RE
03:23aASTRAZENECA : Farxiga clears late-stage heart-failure study
RE
02:26aASTRAZENECA : Farxiga Met Primary Endpoint in Landmark Phase 3 Trial
DJ
08/19ALLERGAN : Form 8.3 - Allergan Plc
DJ
08/19NOVARTIS : to answer U.S. Senate demand for data manipulation details
RE
More sector news : Pharmaceuticals - NEC
Chart MYLAN NV
Duration : Period :
Mylan NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MYLAN NV
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 26,11  $
Last Close Price 19,19  $
Spread / Highest target 82,4%
Spread / Average Target 36,0%
Spread / Lowest Target 4,22%
EPS Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Haribabu Bodepudi Chief Operating Officer
Kenneth Scott Parks Chief Financial Officer
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN NV-29.96%9 900
JOHNSON & JOHNSON2.48%346 681
ROCHE HOLDING LTD.12.24%238 299
MERCK AND COMPANY12.80%217 785
NOVARTIS17.81%204 677
PFIZER-19.40%191 651